PATIENT CONSIDERATIONS

Considering women who may be right for Twirla®

When discussing birth control methods with women in your practice, consider Twirla for women of reproductive potential for whom a combined hormonal contraceptive is appropriate, who have a BMI <30 kg/m2 and who:

WANT
  • A noninvasive birth control option
  • The lowest dose of estrogen available for women who choose a patch1
  • Birth control they can self-administer
DON'T WANT
  • Same-time-every-day dosing, 7 days a week2
  • Daily serum estrogen fluctuations associated with the pill3
  • Birth control that requires an in-office medical procedure to administer
BEFORE PRESCRIBING

If you and your patient think that Twirla may be an appropriate birth control choice, remember the following before prescribing:

  • Twirla has shown reduced effectiveness in women with a BMI ≥25 kg/m2 to <30 kg/m2. Twirla is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).
  • Twirla should be applied to clean, dry, intact skin that has not been exposed to powder, oil, moisturizer, or lotion.
  • Prolonged exposure to water (30 minutes or more) may interfere with the adhesion of Twirla.
The efficacy of Twirla was studied across a range of BMIs. DEMONSTRATED EFFICACY

IMPORTANT SAFETY INFORMATION

+

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥30 kg/m2

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke.

Contraindicated in Women with a BMI ≥30 kg/m2

TWIRLA is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).